When does alectinib’s patent expire?
I don’t have enough information in the provided material to give an exact patent expiry date for alectinib. Patent terms depend on the specific patent family (country-specific filings, priority date, and any term adjustments or extensions).
Which country’s alectinib patent expiry are you looking for?
Alectinib (brand: Alecensa in many markets) can have different “expiry” dates across jurisdictions, because:
- patents are filed in different countries at different times,
- term adjustments/extensions vary by regulator, and
- some drugs have both primary patents and later “secondary” patents (e.g., specific formulations, dosing regimens, or crystal forms).
How can you find the exact expiry date quickly?
To determine the correct expiry for alectinib, you need:
- the jurisdiction (e.g., US, EU/UK, Japan, China),
- the specific patent number or the “family” you’re tracking, and
- the relevant reference date (priority/filing date, and whether there are extensions).
If you share the country (or patent number), I can narrow down the expiry date to the correct patent family.
Are there multiple patents that could block competitors even after one expires?
Yes. Even if one key patent expires, other patents in the same family or “follow-on” patents may still provide protection and delay generic/biosimilar entry (or limit what can be marketed). This is why the “earliest” expiry versus the “last” expiry can differ.
What about exclusivity rules—are they the same as patent expiry?
No. Marketing exclusivity can extend beyond the last patent date, depending on the country’s drug-exclusivity framework. Patent expiry alone often doesn’t predict when a generic can launch.
Tell me what you have, and I’ll pin down the date
If you provide any of the following, I can give a precise expiry for the right item:
- country/region (US, EU, UK, Japan, etc.)
- patent number(s)
- drug label/market (e.g., Alecensa in a specific country)
- whether you mean “first expiry” or “last expiry” across a patent family